Roth Capital Reiterates Buy Rating for Biodesix, Inc.
Roth Capital has reaffirmed its buy rating on Biodesix, Inc., setting a price target of $32, a 37.10% upside from the current price.
Key Points
- Roth Capital reiterated its buy rating on Biodesix, Inc. with a price target of $32 as of June 25, 2026.
- Roth Capital's $32 price target implies 37.10% upside from Biodesix, Inc.'s ($BDSX) current $23.34 share price.
- Biodesix's stock traded near $18.67 on Thursday, with a market cap of approximately $179.7 million.
- Several funds, including AIGH Capital Management and Telemark Asset Management, adjusted their positions in Biodesix recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Roth Capital reiterated its buy rating on Biodesix, Inc. (NasdaqGM: BDSX) on June 25, 2026, maintaining a price target of $32. This suggests confidence in the company's potential growth, as Biodesix shares traded near $18.67 on Thursday.
Roth Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Biodesix, Inc.
AIGH Capital Management LLC opened a new position in Biodesix with 758,328 shares, valued at about $10.9 million. Telemark Asset Management, LLC increased its holdings by 162,000 shares, ending with 489,824 shares worth approximately $7.1 million, marking a 49.4% increase. Aberdeen Group PLC grew its stake by 196,013 shares to a total of 458,438 shares valued at around $6.6 million, a 74.7% increase. Soleus Capital Management, L.P. also initiated a new position, acquiring 416,599 shares worth about $6 million. Meanwhile, Birchview Capital, LP kept its holdings steady at 286,804 shares, valued at $4.2 million.
Biodesix, Inc. Stock Down 13.0%
Shares of NasdaqGM:BDSX traded near $18.67 on Thursday. Biodesix boasts a market cap of approximately $179.7 million, with a beta of 0.593, indicating lower volatility compared to the market. The stock's 52-week range spans from $5.00 to $20.21, with a 50-day moving average of $14.00 and a 200-day moving average of $10.80. The company has a current ratio of 2.82 and a quick ratio of 2.42, though it has a high debt-to-equity ratio of 805.6.
$BDSX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Biodesix reported revenue of $96.1 million, with a year-over-year growth of 42.3%. However, the company posted a net margin of -33.3% and a return on equity of -316.5%, indicating financial challenges. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Biodesix, Inc.
Insider transactions include Patience John, who both sold and bought 1,361 shares on March 31, 2026. On February 23, 2026, multiple executives, including CFO Robin Harper Cowie, Chief Accounting Officer Chris Vazquez, and Chief Commercial Officer Kieran O'Kane, sold 535 shares each at an average price of $12.78. President and CEO Scott Hutton also sold 1,490 shares on the same date.
Analysts Set New Price Targets
On June 25, 2026, Roth Capital reiterated its buy rating for Biodesix, setting a price target of $32. Earlier, on June 18, 2026, Canaccord Genuity maintained a buy rating with a target of $27. HC Wainwright & Co. also initiated coverage with a buy rating and a $26 target on June 15, 2026. The consensus recommendation is a strong buy, with an average target price of $30.60 from five analysts.
About Biodesix, Inc.
Biodesix, Inc. is a healthcare company based in Louisville, Colorado, specializing in diagnostic solutions. It provides blood-based tests for lung cancer risk assessment and treatment guidance through products like Nodify Lung Nodule Risk Assessment and IQLung testing strategy. The company also offers services such as biomarker discovery and clinical trial testing for biopharmaceutical firms. Biodesix employs 334 people and is led by CEO Scott Hutton.
Bottom Line
Roth Capital's reiterated buy rating on Biodesix with a $32 price target highlights ongoing confidence in the company's prospects. The stock's recent trading activity and institutional interest indicate a dynamic market presence. As always, remember that these analyst ratings are backward-looking and may not reflect future performance.
Get Biodesix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BDSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.